Abiopharma

🔍 Allison Schwartz (Director)

Company: BIO-RAD LABORATORIES, INC. (BIO BIO.B)

Report Date: 2025-09-05

Detailed Transactions and Holdings:

• Acquired 92 shares of Bio-Rad A Common Stock (Direct)
  Date: 2025-09-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,489.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 33 shares of Bio-Rad A Common Stock at $295.43 per share (Direct)
  Date: 2025-09-06 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,456.00 | transaction_form_type: 4
• Acquired 914 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 914.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
• Sold 92 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 277.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
• F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
• F3: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.